Skip to main content
PMC home page
British Medical Journal logoLink to British Medical Journal
. 1978 Nov 18;2(6149):1390–1391. doi: 10.1136/bmj.2.6149.1390

Polyunsaturated fatty acids in treatment of acute remitting multiple sclerosis.

D Bates, P R Fawcett, D A Shaw, D Weightman
PMCID: PMC1608620  PMID: 363236

Abstract

One hundred and sixteen patients with acute remitting multiple sclerosis (MS) took part in a double-blind controlled trial of treatment with polyunsaturated fatty acids and were randomly allocated to one of four groups. Two groups received linoleic acid, one alone as a spread and one with gamma-linolenic acid in capsules (Naudicelle); and two control groups received oleic acid, one as a spread and one in capsules. Rates of clinical deterioration and frequencies of attacks were not significantly different between treated and control groups. Exacerbations were shorter and less severe in patients receiving a high dose of linoleic acid than in controls, but those receiving a lower dose--that is, Naudicelle--showed no such difference. Thus supplementing the diet with 20 g linoleic acid marginally affected the duration and severity of relapses of MS but had no effect on overall disability. The dose of Naudicelle used provided insufficient supplementation.

Full text

PDF
1390

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Batchelor J. R. Histocompatibility antigens and their relevance to multiple sclerosis. Br Med Bull. 1977 Jan;33(1):72–77. doi: 10.1093/oxfordjournals.bmb.a071400. [DOI] [PubMed] [Google Scholar]
  2. Field E. J., Shenton B. K. Inhibitory effect of unsaturated fatty acids on lymphocyte-antigen interaction with special reference to multiple sclerosis. Acta Neurol Scand. 1975 Aug;52(2):121–136. doi: 10.1111/j.1600-0404.1975.tb05766.x. [DOI] [PubMed] [Google Scholar]
  3. KURTZKE J. F. On the evaluation of disability in multiple sclerosis. Neurology. 1961 Aug;11:686–694. doi: 10.1212/wnl.11.8.686. [DOI] [PubMed] [Google Scholar]
  4. MEAD J. F., HOWTON D. R. Metabolism of essential fatty acids. VII. Conversion of gamma-linolenic acid to arachidonic acid. J Biol Chem. 1957 Dec;229(2):575–582. [PubMed] [Google Scholar]
  5. Mertin J., Meade C. J. Relevance of fatty acids in multiple sclerosis. Br Med Bull. 1977 Jan;33(1):67–71. doi: 10.1093/oxfordjournals.bmb.a071399. [DOI] [PubMed] [Google Scholar]
  6. Millar J. H., Vas C. J., Noronha M. J., Liversedge L. A., Rawson M. D. Long-term treatment of multiple sclerosis with corticotrophin. Lancet. 1967 Aug 26;2(7513):429–431. doi: 10.1016/s0140-6736(67)90850-1. [DOI] [PubMed] [Google Scholar]
  7. Pelus L. M., Strausser H. R. Prostaglandins and the immune response. Life Sci. 1977 Mar 15;20(6):903–913. doi: 10.1016/0024-3205(77)90274-0. [DOI] [PubMed] [Google Scholar]
  8. SINCLAIR H. M. Deficiency of essential fatty acids and atherosclerosis, etcetera. Lancet. 1956 Apr 7;270(6919):381–383. [PubMed] [Google Scholar]
  9. SWANK R. L. Multiple sclerosis; a correlation of its incidence with dietary fat. Am J Med Sci. 1950 Oct;220(4):421–430. [PubMed] [Google Scholar]
  10. SWANK R. L. Treatment of multiple sclerosis with low-fat diet. AMA Arch Neurol Psychiatry. 1953 Jan;69(1):91–103. doi: 10.1001/archneurpsyc.1953.02320250097011. [DOI] [PubMed] [Google Scholar]
  11. Thompson R. H. A biochemical approach to the problem of multiple sclerosis. Proc R Soc Med. 1966 Mar;59(3):269–276. [PMC free article] [PubMed] [Google Scholar]

Articles from British Medical Journal are provided here courtesy of BMJ Publishing Group

RESOURCES